The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Phase I dose expansion results of izalontamab brenitecan in EGFRm NSCLC
Alexander Spira, MD, PhD, FACP, FASCO, Virginia Cancer Specialists and US Oncology, Fairfax, VA, discusses the results of a Phase I study (NCT05983432) expansion cohort of izalontamab brenitecan (iza-bren), an EGFR x HER3 bispecific antibody conjugate (ADC) in EGFR-mutated non-small cell lung cancer (NSCLC). Response rates were similar across three different doses, but the 2.5 milligram per kilogram dose level showed slightly higher progression-free survival and duration of response, and will be the dose used in the upcoming randomized clinical study comparing iza-bren to chemotherapy post-osimertinib. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the paper and abstract presented here at World Lung is iza-bren. The original study was a phase one study in escalation where they identified the toxicities and got to the MTD. This was the expansion cohort. 81 patients were enrolled and looked at three different doses, 1.5, 2, and 2.5, to really optimize this before going forward in a phase three study. What we found was that the response rates were about the same...
So the paper and abstract presented here at World Lung is iza-bren. The original study was a phase one study in escalation where they identified the toxicities and got to the MTD. This was the expansion cohort. 81 patients were enrolled and looked at three different doses, 1.5, 2, and 2.5, to really optimize this before going forward in a phase three study. What we found was that the response rates were about the same. There was slightly higher progression-free survival and duration of response at the 2.5 milligram per kilogram dose level. So that’s the dose decided on to go forward now in the randomized clinical study, which will be iza-brennversus chemotherapy post-osimertinib. One of the other things we’re obviously looking at is toxicity and side effects, and what we found there were no new safety signals. And in the earlier study, it was found that patients did a little bit better with growth factors, so growth factor was mandatory in this expansion cohort and will be in the future expansion cohorts.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
